Babette M Pluim

Tennis injuries: occurrence, aetiology, and prevention.

A systematic search of published reports was carried out in three electronic databases from 1966 on to identify relevant articles relating to tennis injuries. There were 39 case reports, 49 laboratory studies, 28 descriptive epidemiological studies, and three analytical epidemiological studies. The principal findings of the review were: first, there is a great variation in the reported incidence of tennis injuries; second, most injuries occur in the lower extremities, followed by the upper extremities and then the trunk; third, there have been very few longitudinal cohort studies that investigated the association between risk factors and the occurrence of tennis injuries (odds ratios, risk ratios, hazard ratios); and fourth, there were no randomised controlled trials investigating injury prevention measures in tennis. More methodologically sound studies are needed for a better understanding of risk factors, in order to design useful strategies to prevent tennis injuries.

How much is too much? (Part 2) International Olympic Committee consensus statement on load in sport and risk of illness

Athletes participating in elite sports are exposed to high training loads and increasingly saturated competition calendars. Emerging evidence indicates that poor load management is a major risk factor for injury. The International Olympic Committee convened an expert group to review the scientific evidence for the relationship of load (defined broadly to include rapid changes in training and competition load, competition calendar congestion, psychological load and travel) and health outcomes in sport. We summarise the results linking load to risk of injury in athletes, and provide athletes, coaches and support staff with practical guidelines to manage load in sport. This consensus statement includes guidelines for (1) prescription of training and competition load, as well as for (2) monitoring of training, competition and psychological load, athlete well-being and injury. In the process, we identified research priorities.

Consensus statement on epidemiological studies of medical conditions in tennis, April 2009

Background: The reported incidence, severity and nature of injuries sustained in tennis vary considerably between studies. While some of these variations can be explained by differences in sample populations and conditions, the main reasons are related to differences in definitions and methodologies employed in the studies. Objective: This statement aims to review existing consensus statements for injury surveillance in other sports in order to establish definitions, methods and reporting procedures that are applicable to the specific requirements of tennis. Design: The International Tennis Federation facilitated a meeting of 11 experts from seven countries representing a range of tennis stakeholders. Using a mixed methods consensus approach, key issues related to definitions, methodology and implementation were discussed and voted on by the group during a structured 1-day meeting. Following this meeting, two members of the group collaborated to produce a draft statement, based on the group discussions and voting outcomes. Three revisions were prepared and circulated for comment before the final consensus statement was produced. Results: A definition of medical conditions (injuries and illnesses) that should be recorded in tennis epidemiological studies and criteria for recording the severity and nature of these conditions are proposed. Suggestions are made for recording players’ baseline information together with recommendations on how medical conditions sustained during match play and training should be reported. Conclusions: The definitions and methodology proposed for recording injuries and illnesses sustained during tennis activities will lead to more consistent and comparable data being collected. The surveillance procedures presented here may also be applicable to other racket sports.

Injury and illness definitions and data collection procedures for use in epidemiological studies in Athletics (track and field): Consensus statement

Background Movement towards sport safety in Athletics through the introduction of preventive strategies requires consensus on definitions and methods for reporting epidemiological data in the various populations of athletes. Objective To define health-related incidents (injuries and illnesses) that should be recorded in epidemiological studies in Athletics, and the criteria for recording their nature, cause and severity, as well as standards for data collection and analysis procedures. Methods A 1-day meeting of 14 experts from eight countries representing a range of Athletics stakeholders and sport science researchers was facilitated. Definitions of injuries and illnesses, study design and data collection for epidemiological studies in Athletics were discussed during the meeting. Two members of the group produced a draft statement after this meeting, and distributed to the group members for their input. A revision was prepared, and the procedure was repeated to finalise the consensus statement. Results Definitions of injuries and illnesses and categories for recording of their nature, cause and severity were provided. Essential baseline information was listed. Guidelines on the recording of exposure data during competition and training and the calculation of prevalence and incidences were given. Finally, methodological guidance for consistent recording and reporting on injury and illness in athletics was described. Conclusions This consensus statement provides definitions and methodological guidance for epidemiological studies in Athletics. Consistent use of the definitions and methodological guidance would lead to more reliable and comparable evidence.

β2-Agonists and Physical Performance

Inhaled β₂-agonists are commonly used as bronchodilators in the treatment of asthma. Their use in athletes, however, is restricted by anti-doping regulations. Controversies remain as to whether healthy elite athletes who use bronchodilators may gain a competitive advantage. The aim of this systematic review and meta-analysis is to assess the effects of inhaled and systemic β₂-agonists on physical performance in healthy, non-asthmatic subjects. To this end, MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials (CENTRAL) were searched up to August 2009. Reference lists were searched for additional relevant studies. The search criteria were for randomized controlled trials examining the effect of inhaled or systemic β₂-agonists on physical performance in healthy, non-asthmatic subjects. Two authors independently performed the selection of studies, data extraction and risk of bias assessment. Parallel-group and crossover trials were analysed separately. Mean difference (MD) and 95% confidence intervals were calculated for continuous data and, where possible, data were pooled using a fixed effects model. Twenty-six studies involving 403 participants (age range 7-30 years) compared inhaled β₂-agonists with placebo. No significant effect could be detected for inhaled β₂-agonists on maximal oxygen consumption (VO₂(max)) [MD -0.14 mL · kg⁻¹ · min⁻¹; 95% CI -1.07, 0.78; 16 studies], endurance time to exhaustion at 105-110% VO₂(max) (MD -1.5 s; 95% CI -15.6, 12.6; four studies), 20-km time trial duration (MD -4.4 s; 95% CI -23.5, 14.7; two studies), peak power (MD -0.14 W · kg⁻¹; 95% CI -0.54, 0.27; four studies) and total work during a 30-second Wingate test (MD 0.80 J · kg⁻¹; 95% CI -2.44, 4.05; five studies). Thirteen studies involving 172 participants (age range 7-22 years) compared systemic β₂-agonists with placebo, with 12 studies involving oral and one study involving intravenous salbutamol. A significant effect was detected for systemic β₂-agonists on endurance time to exhaustion at 80-85% VO₂(max) (MD 402 s; 95% CI 34, 770; two studies), but not for VO₂(max) (placebo 42.5 ± 1.7 mL · kg⁻¹ · min⁻¹, salbutamol 42.1 ± 2.9 mL · kg⁻¹ · min⁻¹, one study), endurance time to exhaustion at 70% VO₂(max) (MD 400 s; 95% CI -408, 1208; one study) or power output at 90% VO₂(max) (placebo 234.9 ± 16 W, salbutamol 235.5 ± 18.1 W, one study). A significant effect was shown for systemic β₂-agonists on peak power (MD 0.91 W · kg⁻¹; 95% CI 0.25, 1.57; four studies), but not on total work (MD 7.8 J · kg⁻¹; 95% CI -3.3, 18.9; four studies) during a 30-second Wingate test. There were no randomized controlled trials assessing the effects of systemic formoterol, salmeterol or terbutaline on physical performance. In conclusion, no significant effects were detected for inhaled β₂-agonists on endurance, strength or sprint performance in healthy athletes. There is some evidence indicating that systemic β₂-agonists may have a positive effect on physical performance in healthy subjects, but the evidence base is weak.Inhaled β2-agonists are commonly used as bronchodilators in the treatment of asthma. Their use in athletes, however, is restricted by anti-doping regulations. Controversies remain as to whether healthy elite athletes who use bronchodilators may gain a competitive advantage.The aim of this systematic review and meta-analysis is to assess the effects of inhaled and systemic β2-agonists on physical performance in healthy, nonasthmatic subjects. To this end, MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials (CENTRAL) were searched up to August 2009. Reference lists were searched for additional relevant studies. The search criteria were for randomized controlled trials examining the effect of inhaled or systemic β2-agonists on physical performance in healthy, nonasthmatic subjects. Two authors independently performed the selection of studies, data extraction and risk of bias assessment. Parallel-group and crossover trials were analysed separately. Mean difference (MD) and 95% confidence intervals were calculated for continuous data and, where possible, data were pooled using a fixed effects model.Twenty-six studies involving 403 participants (age range 7–30 years) compared inhaled β2-agonists with placebo. No significant effect could be detected for inhaled β2-agonists on maximal oxygen consumption (V̇O2max) [MD −0.14mL•kg−1•min−1; 95% CI −1.07, 0.78; 16 studies], endurance time to exhaustion at 105–110% V̇O2max (MD −1.5 s; 95% CI −15.6, 12.6; four studies), 20-km time trial duration (MD −4.4 s; 95% CI −23.5, 14.7; two studies), peak power (MD −0.14 W•kg−1; 95% CI −0.54, 0.27; four studies) and total work during a 30-second Wingate test (MD 0.80 J•kg−1; 95% CI −2.44, 4.05; five studies). Thirteen studies involving 172 participants (age range 7–22 years) compared systemic β2-agonists with placebo, with 12 studies involving oral and one study involving intravenous salbutamol. A significant effect was detected for systemic β2-agonists on endurance time to exhaustion at 80–85% V̇O2max (MD 402 s; 95% CI 34, 770; two studies), but not for V̇O2max (placebo 42.5–1.7mL•kg−1•min−1, salbutamol 42.1±2.9mL•kg−1•min−1, one study), endurance time to exhaustion at 70% V̇O2max (MD 400 s; 95%CI −408, 1208; one study) or power output at 90% V̇O2max (placebo 234.9±16 W, salbutamol 235.5±18.1 W, one study). Asignificant effect was shown for systemic β2-agonists on peak power (MD 0.91 W•kg−1; 95% CI 0.25, 1.57; four studies), but not on total work (MD 7.8 J•kg−1; 95% CI −3.3, 18.9; four studies) during a 30-second Wingate test. There were no randomized controlled trials assessing the effects of systemic formoterol, salmeterol or terbutaline on physical performance.In conclusion, no significant effects were detected for inhaled β2-agonists on endurance, strength or sprint performance in healthy athletes. There is some evidence indicating that systemic β2-agonists may have a positive effect on physical performance in healthy subjects, but the evidence base is weak.

A one-season prospective study of injuries and illness in elite junior tennis

The objective of this study was to estimate the incidence and prevalence of injury and illness among elite junior tennis players. A cohort of 73 players (11–14 years) in the 2012–2013 Dutch national high‐performance program was followed for 32 weeks; all participants completed the study. The OSTRC Questionnaire on Health Problems was used to record self‐reported injuries and illnesses and to record training and match exposure. Main outcome measures were average prevalence of overuse injury and illness and incidence density of acute injury. On average, players practiced 9.1 h/week (SD 0.6; range 2.3–12.0) and had 2.2 h of match play (SD 0.6; range 2.3–12.0). During the course of the study, 67 players reported a total of 187 health problems. The average weekly prevalence of all health problems was 21.3% (95% CI: 19.2–22.9), of which 12.1% (95% CI: 10.9–13.3) constituted overuse injuries and 5.8% (95% CI: 4.6–6.9) illnesses. The incidence of acute injuries was 1.2/1000 h of tennis play (95% CI: 0.7–1.7). The high occurrence of overuse injuries among elite junior tennis players suggests that an early focus on preventative measures is warranted, with a particular focus on the monitoring and management of workload.

Consensus recommendations on training and competing in the heat

Exercising in the heat induces thermoregulatory and other physiological strain that can lead to impairments in endurance exercise capacity. The purpose of this consensus statement is to provide up‐to‐date recommendations to optimize performance during sporting activities undertaken in hot ambient conditions. The most important intervention one can adopt to reduce physiological strain and optimize performance is to heat acclimatize. Heat acclimatization should comprise repeated exercise‐heat exposures over 1–2 weeks. In addition, athletes should initiate competition and training in a euhydrated state and minimize dehydration during exercise. Following the development of commercial cooling systems (e.g., cooling vest), athletes can implement cooling strategies to facilitate heat loss or increase heat storage capacity before training or competing in the heat. Moreover, event organizers should plan for large shaded areas, along with cooling and rehydration facilities, and schedule events in accordance with minimizing the health risks of athletes, especially in mass participation events and during the first hot days of the year. Following the recent examples of the 2008 Olympics and the 2014 FIFA World Cup, sport governing bodies should consider allowing additional (or longer) recovery periods between and during events for hydration and body cooling opportunities when competitions are held in the heat.

Health Benefits of Tennis

The aim of the study was to explore the role of tennis in the promotion of health and prevention of disease. The focus was on risk factors and diseases related to a sedentary lifestyle, including low fitness levels, obesity, hyperlipidaemia, hypertension, diabetes mellitus, cardiovascular disease, and osteoporosis. A literature search was undertaken to retrieve relevant articles. Structured computer searches of PubMed, Embase, and CINAHL were undertaken, along with hand searching of key journals and reference lists to locate relevant studies published up to March 2007. These had to be cohort studies (of either cross sectional or longitudinal design), case–control studies, or experimental studies. Twenty four studies were identified that dealt with physical fitness of tennis players, including 17 on intensity of play and 16 on maximum oxygen uptake; 17 investigated the relation between tennis and (risk factors for) cardiovascular disease; and 22 examined the effect of tennis on bone health. People who choose to play tennis appear to have significant health benefits, including improved aerobic fitness, a lower body fat percentage, a more favourable lipid profile, reduced risk for developing cardiovascular disease, and improved bone health.

Blood glucose responses and incidence of hypoglycaemia in elite tennis under practice and tournament conditions

The purpose of the study was to specify the changes in blood glucose concentrations in the course of repeated tournament and practice matches, and to quantify the Incidence of hypoglycaemia in elite tennis players. The study consisted of two parts. In the first, 147 tournament players completed a questionnaire about the incidence of hypoglycaemic symptoms during repeated tennis matches. In the second part of the study, the players participated in two subsequent matches (one singles match followed by a doubles) under (T) tournament (n = 57) and (P) practice (n = 20) conditions. Of the 147 players consulted, 94 (63.9%) reported experiences with hypoglycaemic symptoms during a tennis tournament (n = 80) and/or tennis practice (n = 62). The warm-up period for the second match day was identified as the most sensitive point for the occurrence of hypoglycaemic symptoms (n = 29), compared to the final stages of the first (n = 11) or second match (n = 7). Under both practice and tournament conditions, a significant (p < 0.01) drop in blood glucose concentration was found during the warm-up period for the second match per day (T: from 5.8 +/- 1.4 mmol x L(-1) to 4.3 +/- 0.8 mmol x L(-1) and P: from 5.4 +/- 1.1 mmol x L(-1) to 4.1 +/- 1.5 mmol x L(-1)). In conclusion, precautions should be taken to prevent a sudden drop in blood glucose concentration and hypoglycaemic symptoms during the early stages of a players second tennis match in one day.

Scapular dyskinesis: practical applications

Goran Ivanisevic had a career-limiting shoulder injury, Martin Verkerk took almost 2 years for his shoulder rehabilitation and Johan Santana is out for this season after re-injuring his shoulder. You are confronted with a tennis player presenting with pain when serving. Does your heart sink? To address these problems, Dr Ben Kibler spearheaded the 2nd International Conference on the Scapula in Lexington, Kentucky in July 2012. You can read the consensus paper from this conference in the September issue of the BJSM 1; you can listen to podcasts with Dr Kibler on the BJSM website. What are the practical applications for clinicians working with overhead athletes? The main focus of the conference was scapular dyskinesis—altered motion and positioning of the scapula.1 ,2 This condition is frequently found in athletes with shoulder injuries but can also be present in asymptomatic individuals. Its exact role in shoulder dysfunction is unknown. It is still unclear whether it is the cause or an effect of shoulder injuries (a compensatory mechanism for shoulder pathology). The shoulder consensus group agreed that scapular dyskinesis is …